
暫無股票
Asensus Shares First Quarter Results and Future Plans
Asensus Surgical Has Received A Notice Of Allowance For Its U.S. Patent Application 16/932,654 Titled "Compact Actuation Configuration And Expandable Instrument Receiver For Robotically Controlled Surgical Instruments"
Asensus Surgical 已收到其美國專利申請 16/932,654 的許可通知,其標題為 “用于機器人控制的 Sur 的緊湊型致動配置和可擴展儀器接收器”
Asensus Surgical Price Target Maintained With a $2.00/Share by HC Wainwright & Co.
HC Wainwright & Co.維持Asensus手術目標股價為每股2.00美元
H.C. Wainwright Sticks to Its Buy Rating for Asensus Surgical (ASXC)
Asensus Surgical Down 5% on Q1 Misses
Asensus Surgical Q1 Adj EPS $(0.09) Down From $(0.07) YoY, Sales $976.00K Down From $1.07M YoY
Asensus Surgical(AMEX: ASXC)公布的季度每股虧損為0.09美元。與去年同期相比,每股虧損0.07美元下降了28.57%。該公司報告了97美元
Asensus Surgical Non-GAAP EPS of -$0.09 Misses by $0.02, Revenue of $0.98M Misses by $0.62M
Press Release: Asensus Surgical, Inc. Reports Operating and Financial Results for the First Quarter 2023
Asensus Surgical, Inc. 公布了2023年第一季度的運營和財務業績,北卡羅來納州研究三角公園,2023年5月11日(GLOBE NEWSWIRE)— Asensus Surgical, Inc.(紐約證券交易所美國股票代碼:ASXC),
Earnings Scheduled For May 11, 2023
鐘聲來臨前的公司 ? 武田制藥(紐約證券交易所代碼:TAK)可能會公布其第四季度的收益。? Exela Technologies(納斯達克股票代碼:XELA)預計將公布其財報
Asensus Surgical Q1 2023 Earnings Preview
加載中...
暫無股票